These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. Le Corre P; Gibassier D; Sado P; Le Verge R Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466 [TBL] [Abstract][Full Text] [Related]
3. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. Lima JJ; Haughey DB; Leier CV J Pharmacokinet Biopharm; 1984 Jun; 12(3):289-313. PubMed ID: 6502472 [TBL] [Abstract][Full Text] [Related]
4. Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function. Pedersen LE; Bonde J; Graudal NA; Backer NV; Hansen JE; Kampmann JP Br J Clin Pharmacol; 1987 Jan; 23(1):41-6. PubMed ID: 3814461 [TBL] [Abstract][Full Text] [Related]
5. The influence of age and smoking on the elimination of disopyramide. Bonde J; Pedersen LE; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP Br J Clin Pharmacol; 1985 Nov; 20(5):453-8. PubMed ID: 4074615 [TBL] [Abstract][Full Text] [Related]
6. Elimination kinetics and urinary excretion of disopyramide in human healthy volunteers. Bonde J; Jensen NM; Pedersen LE; Graudal NA; Angelo HR; Kampmann JP Pharmacol Toxicol; 1988 May; 62(5):298-301. PubMed ID: 3413032 [TBL] [Abstract][Full Text] [Related]
7. Protein binding of disopyramide in liver cirrhosis and in nephrotic syndrome. Echizen H; Saima S; Umeda N; Ishizaki T Clin Pharmacol Ther; 1986 Sep; 40(3):274-80. PubMed ID: 3742934 [TBL] [Abstract][Full Text] [Related]
8. Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure. Bonde J; Angelo HR; Bødtker S; Svendsen TL; Kampmann JP Acta Pharmacol Toxicol (Copenh); 1985 Apr; 56(4):278-82. PubMed ID: 4024955 [TBL] [Abstract][Full Text] [Related]
9. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide. Bredesen JE; Kierulf P Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986 [TBL] [Abstract][Full Text] [Related]
10. Stereoselective pharmacokinetics of disopyramide enantiomers in man. Lima JJ; Boudoulas H; Shields BJ Drug Metab Dispos; 1985; 13(5):572-7. PubMed ID: 2865105 [TBL] [Abstract][Full Text] [Related]
11. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Haughey DB; Kraft CJ; Matzke GR; Keane WF; Halstenson CE Am J Nephrol; 1985; 5(1):35-9. PubMed ID: 3881959 [TBL] [Abstract][Full Text] [Related]
12. Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein. Haughey DB; Steinberg I; Lee MH J Pharm Pharmacol; 1985 Apr; 37(4):285-8. PubMed ID: 2860235 [TBL] [Abstract][Full Text] [Related]
13. Disposition kinetics of disopyramide in human healthy volunteers described by an open three compartment model. Bonde J; Jensen NM; Pedersen LE; Angelo HR; Rasmussen SN; Trap-Jensen J; Kampmann JP Pharmacol Toxicol; 1989 May; 64(5):412-6. PubMed ID: 2771866 [TBL] [Abstract][Full Text] [Related]
15. Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment? Braun J; Sörgel F; Gluth WP; Oie S Eur J Clin Pharmacol; 1988; 35(3):313-7. PubMed ID: 3181285 [TBL] [Abstract][Full Text] [Related]
16. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics. Lima JJ; Boudoulas H; Blanford M J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695 [TBL] [Abstract][Full Text] [Related]
17. Disopyramide kinetics in renal impairment: determinants of interindividual variability. Burk M; Peters U Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909 [TBL] [Abstract][Full Text] [Related]